ASH 2022 | Results from the Phase I SAL-RELAX trial: venetoclax plus cytarabine and mitoxantrone in R/R AML
Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, outlines the results of the Phase I SAL-RELAX trial (NCT04330820), which investigated whether combining standard cytoreductive high-dose cytarabine and mitoxantrone with the BCL2 inhibitor venetoclax could increase response to salvage in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). Results demonstrated that it is safe and feasible to combine these agents, with a high response rate observed. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BMS: Consultancy, Honoraria; Amgen: Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; Servier: Consultancy; Jazz: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria.
